Twinbeech Capital LP Vir Biotechnology, Inc. Transaction History

Twinbeech Capital LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$7.76 - $10.29 $1.71 Million - $2.27 Million	220,712 Added 222.58%	319,872 $3.22 Million
Q3 2023 Nov 14, 2023	BUY	$9.14 - $24.62 $906,322 - $2.44 Million	99,160 New	99,160 $929,000
Q1 2023 May 15, 2023	BUY	$22.26 - $30.85 $2.42 Million - $3.35 Million	108,507 New	108,507 $2.52 Million
Q3 2022 Nov 14, 2022	BUY	$18.26 - $31.1 $3.02 Million - $5.15 Million	165,460 New	165,460 $3.19 Million
Q2 2022 Aug 15, 2022	SELL	$19.08 - $26.7 $415,982 - $582,113	-21,802 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$21.19 - $40.01 $461,984 - $872,298	21,802 New	21,802 $561,000
Q4 2021 Feb 14, 2022	SELL	$30.97 - $54.03 $1.73 Million - $3.02 Million	-55,974 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$34.9 - $54.54 $1.95 Million - $3.05 Million	55,974 New	55,974 $2.44 Million

230

90.1M

1.28M

235K

Ticker VIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 132,638,000
Market Cap $1.28B
Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...

Get notified when there are updates to the investment portfolio of Twinbeech Capital LP, based on Form 13F filings with the SEC.

Stay updated on Twinbeech Capital LP with notifications on news.